It's dropping because there's other therapeutics hitting the market soon... Unless Leo gets emergency use data will not matter... A phase 3 is not in-the-cards... Been saying this for a year... The costs and time to complete would not be worth the revenue potential which is a big fat DON'T KNOW or HAVE a CLUE...
I think providing an estimated date is very responsible of Leo. No one had a clue where we were at on the results, which means a whole lot for longs. I know Merck and PFE have been given frequent updates on their antivirals, should be no difference for us. I’m just not sure why it takes us longer to get a PhII trial of 120 patients longer than Merck and PFE getting through both PHII and PIII trials. Granted EUA is given on an interim look at Merck’s antiviral.